DekaBank Deutsche Girozentrale’s Castle Biosciences CSTL Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,900	Closed	-$176K	–	1264
2023 Q1	$176K	Hold	7,900	–	–	﹤0.01%	1200
2022 Q4	$183K	Hold	7,900	–	–	﹤0.01%	1233
2022 Q3	$203K	Hold	7,900	–	–	﹤0.01%	1225
2022 Q2	$182K	Hold	7,900	–	–	﹤0.01%	1206
2022 Q1	$348K	Buy	7,900 +700	+10%	+$28.9K	﹤0.01%	1124
2021 Q4	$296K	Buy	7,200 +200	+3%	+$10.5K	﹤0.01%	1194
2021 Q3	$454K	Hold	7,000	–	–	﹤0.01%	1070
2021 Q2	$523K	Hold	7,000	–	–	﹤0.01%	1061
2021 Q1	$435K	Hold	7,000	–	–	﹤0.01%	1051
2020 Q4	$468K	Buy	+7,000	New	+$379K	﹤0.01%	1031

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CSTL Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 7,900 shares — an estimated $176K sold.

DekaBank Deutsche Girozentrale first reported a position in CSTL in Q4 2020 and held it in 10 quarters. The position peaked at $523K in Q2 2021. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

DekaBank Deutsche Girozentrale reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 7,900 Castle Biosciences shares in Q2 2023, an estimated $176K.
DekaBank Deutsche Girozentrale first reported a position in Castle Biosciences in Q4 2020 and held it in 10 quarters.
DekaBank Deutsche Girozentrale's Castle Biosciences position peaked at $523K in Q2 2021.
130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.